Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.
The combination of mitoxantrone with lucanthone, a schistosomicidal and nonmyelotoxic agent, yielded a therapeutic synergism in L 1210 and P 388 leukemia with no increase in toxicity. In that combination the nonmyelotoxic lucanthone enabled the use of the optimal dose of mitoxantrone. The recent hypothesis that planar polycyclic aromatic compounds, mostly comprised by the term intercalators, intercalate with DNA or bind to DNA may need receiving with respect to membrane target sites.
D000818:Animals; D000880:Anthraquinones / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D005260:Female; D007364:Intercalating Agents / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy*; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008154:Lucanthone / Q000627:therapeutic use*; D051379:Mice; D008811:Mice, Inbred DBA; D008942:Mitoxantrone; D009368:Neoplasm Transplantation; D013047:Specific Pathogen-Free Organisms; D013997:Time Factors
D000880:Anthraquinones; D007364:Intercalating Agents; D008942:Mitoxantrone; D008154:Lucanthone